Navigation Links
Arena Pharmaceuticals Announces Third Quarter 2008 Financial Results
Date:10/30/2008

Arena Pharmaceuticals(R) and Arena(R) are registered service marks of the company. "APD" is an abbreviation for Arena Pharmaceuticals Development.

Forward-Looking Statements

Certain statements in this press release are forward-looking statements that involve a number of risks and uncertainties. Such forward-looking statements include statements about Arena's ability and efforts to navigate the economic environment; the prioritization of the lorcaserin program; the redemption of the Series B Convertible Preferred Stock in cash; future results of clinical trials; advancement of Arena's pipeline; therapeutic indication, tolerability, side effects, efficacy and potential of Arena's or its collaborators' product candidates and compounds; financial guidance; and other statements about Arena's focus, strategy, internal and partnered programs, and ability to develop compounds and commercialize drugs. For such statements, Arena claims the protection of the Private Securities Litigation Reform Act of 1995. Actual events or results may differ materially from Arena's expectations. Factors that could cause actual results to differ materially from the forward-looking statements include, but are not limited to, clinical trials and studies may not proceed at the time or in the manner Arena expects or at all, the results of clinical trials or preclinical studies may not be predictive of future results, Arena's ability to receive regulatory approval for its drug candidates, Arena's ability to partner lorcaserin, APD125, APD791 or other of its compounds or programs, the timing, success and cost of Arena's research, out-licensing endeavors and clinical trials, Arena's ability to obtain additional financing, Arena's ability to obtain and defend its patents, and the timing and receipt of payments and fees, if any, from Arena's collaborators. Additional factors that could cause actual results to differ materially from those stated or implied by Arena's forward-looking sta
'/>"/>

SOURCE Arena Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine news :

1. Childrens Miracle Network and Arena Football League Partner for First Nationwide Celebration Event
2. Field Poll: California Nurses Association Most Favorably Viewed Group in Healthcare Arena
3. Arena Pharmaceuticals to Report First Quarter 2008 Financial Results and to Host Conference Call and Webcast on Wednesday, May 7, 2008
4. Arena Pharmaceuticals to Present at the Morgan Stanley Global Healthcare Unplugged Conference
5. Arena Pharmaceuticals Lorcaserin for Obesity Passes Major Safety Milestone
6. Arena Pharmaceuticals to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference
7. Arena Pharmaceuticals Announces Pricing of Public Offering of Common Stock
8. Arena Pharmaceuticals to Present at the BIOCOM Investor Conference
9. Arena Pharmaceuticals Announces Public Offering of Common Stock
10. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
11. Poniard Pharmaceuticals Reports Third Quarter 2008 Financial Results and Corporate Update
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... 11, 2014 The International Concussion ... at the Best Buy Theater in Times Square, ... to the growing concussion epidemic that is plaguing ... levels of competition. , The Symposium gathers more ... researchers, coaches, professional athletes and legal scholars for ...
(Date:7/11/2014)... Newport Beach, CA (PRWEB) July 11, 2014 ... product pure Artichoke Leaf Extract dietary supplements to aid ... flow, an action necessary to facilitate metabolism of fat. ... facilities, Superior Labs Artichoke Leaf Extract is available in ... of pure artichoke extract. , Health Benefits of ...
(Date:7/11/2014)... (PRWEB) July 11, 2014 ... begin this August in New York. ... cover: , -Myofascial Trigger Point Therapy, ... -Mobilization & Thrust Manipulation, -Neuroobilization & Neurodynamics, ... prescribing to a single, isolated manual therapy ...
(Date:7/11/2014)... TX (PRWEB) July 11, 2014 Plasma ... of blood products industry. Although the closure of 16 ... major disruption to domestic blood products market, the total ... 2.8% year on year and total lot release volume ... due to stock consumption, insufficient utilization of new plasma ...
(Date:7/11/2014)... (PRWEB) July 11, 2014 This morning(July 9th, ... 13--Good Morning Memphis to discuss the illegal immigration crisis at ... town of McAllen, Texas. , Dr. Flinn told Good Morning ... is absolutely wide open… The problem is that they do ... Thousands of people per day are coming into the border; ...
Breaking Medicine News(10 mins):Health News:The International Concussion Organization 501(c)(3) hosts its 1st Annual Concussion Symposium at the Best Buy Theater in Time Square, NYC, July 17th, 2014. 2Health News:Artichoke Leaf Extract Released by SuperiorLabs Now Available on Amazon.com With 2 Day Prime Shipping 2Health News:Artichoke Leaf Extract Released by SuperiorLabs Now Available on Amazon.com With 2 Day Prime Shipping 3Health News:Hands-On Seminars, the Leader in Manual Therapy Continuing Education, Announces Series of Comprehensive Hands-On Training Courses 2Health News:Chinese Blood Product Industry Report 2014-2017 Focuses Plasma Volume & Stations Says A New Research Available at ChinaMarketResearchReports.com 2Health News:Chinese Blood Product Industry Report 2014-2017 Focuses Plasma Volume & Stations Says A New Research Available at ChinaMarketResearchReports.com 3Health News:Chinese Blood Product Industry Report 2014-2017 Focuses Plasma Volume & Stations Says A New Research Available at ChinaMarketResearchReports.com 4Health News:Senate Candidate, George Flinn on Fox13 NEWS About the Border Crisis 2
... developed deposits, study finds , , WEDNESDAY, Feb. 4 (HealthDay ... sickened more than 50,000 kids last fall resulted in ... developing kidney problems, according to just-released Beijing research on ... in Taiwan and 10 percent of those who drank ...
... (AUA) will hold its Annual Scientific Meeting in Chicago, ... Meeting is the largest meeting of urologic professionals in ... urologists and healthcare professionals from around the world. This ... more than 300 exhibitors will showcase their products and ...
... Pharmacies will host an in-store Healthy Heart Event., ... well as provide information to help patients better ... Pharmacists will also help patients, ... blood pressure and heart disease., WHY: ...
... /PRNewswire-FirstCall/ -- Bionovo, Inc. (Nasdaq: ... will be presenting at the National Cancer Institute,s Office ... series. The title of the presentation is "Selective Cytotoxic ... Effects in Patients with Advanced Breast Cancer," and will ...
... provider of complete solutions for the analysis of Next ... Molecular Biology Laboratory (EMBL) installed a Genomatix Mining Station ... Facility. These systems deliver the only complete and integrated ... generated by the sequencer, to a molecular level understanding ...
... is seeking nominations for the Fourth Annual Bioscience Awards ... interested in nominating a company or individual for an ... are: Entrepreneurial, Best New Product or Progress, Leadership in ... submit documentation and narratives that fulfill several criteria and ...
Cached Medicine News:Health News:Tainted China Formula Caused High Rate of Kidney Stones in Kids 2Health News:Tainted China Formula Caused High Rate of Kidney Stones in Kids 3Health News:Bionovo Announces Presentation at the National Cancer Institute 2Health News:Bionovo Announces Presentation at the National Cancer Institute 3Health News:EMBL GeneCore purchases Genomatix's next generation sequencing data analysis solution 2Health News:EMBL GeneCore purchases Genomatix's next generation sequencing data analysis solution 3Health News:GBC Seeks Nominations for Fourth Annual Bioscience Awards 2
(Date:7/10/2014)... , July 11, 2014  Major advances in ... cancer are being highlighted in a three-day Oncology ... from 10-12 July, 2014.  Renowned national and international cancer ... best practices and exchange knowledge on modern technologies ... and efficient. The Summit will ...
(Date:7/10/2014)... Virginia , 11. Juli 2014 ... von Kameras für die molekulare Bildgebung, ... hat heute die CE-Zulassung für sein ... CE-Zeichen kann Dilon das Produkt jetzt ... auf den Großteil der europäischen Länder ...
(Date:7/10/2014)... July 10, 2014  The U.S. Department of Health ... to University Hospitals (UH) Case Medical Center Seidman Cancer ... model aimed at improving care for patients with complex ... project will test a unique model developed at UH ... disease, significant comorbidities, or demonstrated need for high health ...
Breaking Medicine Technology:Improving quality and access to advanced cancer care in India and South Asia 2Improving quality and access to advanced cancer care in India and South Asia 3Improving quality and access to advanced cancer care in India and South Asia 4Improving quality and access to advanced cancer care in India and South Asia 5Dilon erhält CE-Zulassung für sein Navigator-Gamma-Sondensystem 2University Hospitals Case Medical Center Awarded $4.7 Million Grant from U.S. Department of Health and Human Services 2University Hospitals Case Medical Center Awarded $4.7 Million Grant from U.S. Department of Health and Human Services 3University Hospitals Case Medical Center Awarded $4.7 Million Grant from U.S. Department of Health and Human Services 4
... /PRNewswire/ -- Treatment of,coronary artery disease (CAD) appears to ... study published today in The,American Journal of Cardiology. , ... 10.6 percent from 2002 to 2005, possibly due,to broader ... as well as declines in risk factors like smoking. ...
... Research from Non-clinical Studies Presented at the ... Symposia Molecular,Targets for Cancer Meetings Support Phase ... March 20, 2007,/PRNewswire-FirstCall/ -- Sunesis Pharmaceuticals, Inc. ... SNS-314, at,two leading scientific meetings focused on ...
Cached Medicine Technology:Hospitalization Rates for Coronary Artery Disease Decline in the,U.S. 2Hospitalization Rates for Coronary Artery Disease Decline in the,U.S. 3Sunesis Pharmaceuticals Presents SNS-314 Aurora Kinase Inhibitor,Data Showing Broad Anti-Tumor Activity, Dosing Flexibility 2Sunesis Pharmaceuticals Presents SNS-314 Aurora Kinase Inhibitor,Data Showing Broad Anti-Tumor Activity, Dosing Flexibility 3
Series I Small Joint Arthroscopy Hand Instruments feature small yet durable instruments specifically designed for small joint arthroscopy. They are available in a variety of low profile styles: strai...
Series I Small Joint Arthroscopy Hand Instruments feature small yet durable instruments specifically designed for small joint arthroscopy. They are available in a variety of low profile styles: strai...
Series I Small Joint Arthroscopy Hand Instruments feature small yet durable instruments specifically designed for small joint arthroscopy. They are available in a variety of low profile styles: strai...
Series I Small Joint Arthroscopy Hand Instruments feature small yet durable instruments specifically designed for small joint arthroscopy. They are available in a variety of low profile styles: strai...
Medicine Products: